University professor proposes changes to US drug safety system
In a report published in the Journal of the American Medical Association, Dr Brian Strom, professor of public health and preventive medicine and chair of the department of
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).